# Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

> **NCT04298983** · PHASE2 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 9 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abemaciclib 150 MG by mouth twice daily
- **DRUG:** Androgen deprivation therapy (ADT)
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04298983
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-09-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Abemaciclib efficacy
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04298983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04298983, "Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04298983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*